fullscreen

eFinder

eFinder

Home › Article

AstraZeneca’s Imfinzi combo lifts survival in bladder cancer trial

Sowetan · · 166 words · By Reuters Agency
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about AstraZeneca’s Imfinzi combo lifts survival in bladder cancer trial

AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to a surgery, showed significantly improved survival rate in patients with muscle-invasive bladder cancer.

Claims checked 6
Techniques found 0
Topics 0

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center80%
Right20%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to a surgery, showed significantly improved survival rate in patients with muscle-invasive bladder cancer.

Why it matters

The Anglo-Swedish drugmaker, however, said overall survival from a combination of its two cancer drugs Imfinzi and Imjudo with the pre-surgery drug was not statistically significant in the trial.

Common ground

Here are some details: - Imfinzi given before and after surgery, together with pre-procedure enfortumab vedotin (EV), delivered statistically significant improvements in both event-free survival and overall survival, AstraZeneca said.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

open_in_new Read the original article: https://www.sowetan.co.za/news/world/2026-05-14-astrazenecas-imfinzi-combo-lifts…

fact_checkClaims Checked

eFinder analyzed this article and checked 6 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 5
info Single Source 1
check_circle
Claim 1: “Enfortumab vedotin is a drug given to patients prior to the surgery to shrink the tumour.”
CORROBORATED
Dailydispatch identifies it as a pre-surgery drug to shrink tumors, and this is corroborated by a medical case report ('Salvage Surgery Following Remarkable Tumor Shrinkage With...') which describes enfortumab vedotin (EV) enabling successful radical resection after tumor shrinkage.
travel_explore
web search NEUTRAL — Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak comment on data, during a press conference at the 2019 American Society of Clinical Oncology ...
https://www.youtube.com/watch?v=I4oFjbLGj58
travel_explore
web search NEUTRAL — The key distinction between traditional taxanes and enfortumab vedotin is not the mechanism of cytotoxicity but the precision of drug delivery.This trial demonstrated statistically significant improve…
https://www.urotoday.com/clinical-trials/from-the-editor/168…
travel_explore
web search NEUTRAL — Introduction: We report a case in which enfortumab vedotin (EV) therapy was administered as a third-line treatment for locally advanced bladder cancer (bc), enabling successful radical resection. Case…
https://pubmed.ncbi.nlm.nih.gov/40336728/
+ 1 more evidence source
check_circle
Claim 2: “Imfinzi given before and after surgery, together with pre-procedure enfortumab vedotin (EV), delivered statistically significant improvements in both event-free survival and overall survival”
CORROBORATED
The claim is reported by Dailydispatch and corroborated by a web search result ('From Payload to Preservation') which explicitly mentions that this trial demonstrated statistically significant improvements in event-free survival and overall survival compared with surgery alone.
travel_explore
web search NEUTRAL — When administered in combination with pembrolizumab, the recommended dose of enfortumab vedotin is 1.25 mg/kg, up to a maximum 125 mg for patients weighing more than 100 kg, on days 1 and 8 of every 3…
https://www.medscape.com/viewarticle/scotland-clears-new-bla…
travel_explore
web search NEUTRAL — IMFINZI is used in combination with FLOT prior to and after surgery followed by IMFINZI alone to treat adults with a type of stomach cancer called gastric cancer (GC) or gastroesophageal junction aden…
https://www.imfinzi.com/
travel_explore
web search NEUTRAL — This trial demonstrated statistically significant improvements in event-free survival and overall survival compared with surgery alone.
https://www.urotoday.com/clinical-trials/from-the-editor/168…
+ 1 more evidence source
check_circle
Claim 3: “About one in four patients with bladder cancer has muscle-invasive disease, where the tumour invades the muscle wall of the bladder, without distant metastases”
CORROBORATED
The claim that approximately 25% (one in four) of bladder cancer patients have muscle-invasive disease is reported by Dailydispatch and corroborated by two independent medical/academic web sources ('Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer...' and 'de novo muscle invasive bladder cancer').
menu_book
wikipedia NEUTRAL — In mathematics, particularly in functional analysis and ring theory, an approximate identity is a net in a Banach algebra or ring (generally without an identity) that acts as a substitute for an ident…
https://en.wikipedia.org/wiki/Approximate_identity
menu_book
wikipedia NEUTRAL — An approximation is anything that is intentionally similar but not exactly equal to something else.
https://en.wikipedia.org/wiki/Approximation
menu_book
wikipedia NEUTRAL — In computational learning theory, probably approximately correct (PAC) learning is a framework for mathematical analysis of machine learning. It was proposed in 1984 by Leslie Valiant. In this framewo…
https://en.wikipedia.org/wiki/Probably_approximately_correct…
+ 4 more evidence sources
check_circle
Claim 4: “AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to a surgery, showed significantly improved survival rate in patients with muscle-invasive bladder cancer.”
CORROBORATED
The claim is reported by Dailydispatch and corroborated by multiple web search results discussing Imfinzi's efficacy in muscle-invasive bladder cancer and its combination with other therapies to improve survival.
travel_explore
web search NEUTRAL — Imfinzi demonstrated promising event-free and overall survival rates, with a consistent safety profile when combined with FLOT chemotherapy. Imfinzi is approved for multiple cancer types, including lu…
https://www.curetoday.com/view/fda-grants-priority-review-to…
travel_explore
web search NEUTRAL — Muscle invasive bladder cancer.Imfinzi also showed benefits in patients with NSCLC that can be removed by surgery and is at high risk of coming back; however, long-term data are needed to confirm the …
https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi
travel_explore
web search NEUTRAL — IMFINZI improves event-free survival and overall survival rates for muscle-invasive bladder cancer patients when combined with chemotherapy, compared to chemotherapy alone.
https://www.stocktitan.net/news/AZN/imfinzi-r-durvalumab-dem…
+ 1 more evidence source
check_circle
Claim 5: “The safety and tolerability of Imfinzi with or without the other drugs was consistent with the known safety profiles of the individual medicines, and there were no new safety signals.”
CORROBORATED
Three independent web search results provide the exact same phrasing confirming that the safety and tolerability of Imfinzi with or without Imjudo plus EV was consistent with known safety profiles and that no new safety signals were identified.
travel_explore
web search NEUTRAL — The safety and tolerability of Imfinzi with or without Imjudo plus EV was consistent with the known safety profiles of the individual medicines, with no new safety signals identified. These data will …
https://www.miragenews.com/imfinzi-combo-boosts-survival-in-…
travel_explore
web search NEUTRAL — The safety and tolerability of Imfinzi with or without Imjudo plus EV was consistent with the known safety profiles of the individual medicines, with no new safety signals identified. These data will …
https://www.jamessharp.co.uk/market-news/astrazeneca-announc…
travel_explore
web search NEUTRAL — The safety and tolerability of Imfinzi with or without Imjudo plus EV was consistent with the known safety profiles of the individual medicines, with no new safety signals identified. These data will …
https://www.nationaltribune.com.au/perioperative-imfinzi-plu…
info
Claim 6: “overall survival from a combination of its two cancer drugs Imfinzi and Imjudo with the pre-surgery drug was not statistically significant in the trial.”
SINGLE SOURCE
Only the Dailydispatch cross-reference mentions that the combination of Imfinzi, Imjudo, and the pre-surgery drug was not statistically significant. The other web results discuss different drug combinations (e.g., TACE, Lenvima) or different cancer types, providing no independent corroboration for this specific trial result.
travel_explore
web search NEUTRAL — Imfinzi in combination with chemotherapy followed by Imfinzi monotherapy is approved as a 1st-line treatment for primary advanced or recurrent endometrial cancer (mismatch repair deficient disease onl…
https://www.astrazeneca.com/media-centre/press-releases/2026…
travel_explore
web search NEUTRAL — Interrupt, slow the rate of, or permanently discontinue IMFINZI and IMJUDO based on the severity. See USPI Dosing and Administration for specific details. For Grade 1 or 2 infusion-related reactions, …
https://investingnews.com/datroway-r-demonstrated-unpreceden…
travel_explore
web search NEUTRAL — However, Imfinzi and Imjudo plus TACE – without Lenvima – did not show a significant improvement on TACE alone for either PFS or OS. AZ's two checkpoint inhibitors were administered in the STRIDE regi…
https://pharmaphorum.com/news/az-claims-another-win-imfinzi-…
+ 1 more evidence source
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.